U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234474) titled 'A Phase I Study of YK012 in Primary Membranous Nephropathy' on Nov. 14.
Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Primary Membranous Nephropathy
Intervention:
DRUG: YK012
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Excyte B...